EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Atherosclerotic cardiovascular disease and inflammatory bowel disease: epidemiology, pathogenesis and risk assessment

Pierluigi Puca, Gaetano Coppola, Simone Parello, Ivan Capobianco, Stefania Colantuono, Franco Scaldaferri, Alfredo Papa

Best Practice & Research Clinical Gastroenterology · 2025-09 · 78 · 102056

DOI: 10.1016/j.bpg.2025.102056 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2025-09. Verfasst von Pierluigi Puca und 6 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Disease Center "CeMAD", Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, 00168, Italy…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Atherosclerosis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel diseases (IBD) are systemic inflammatory conditions increasingly recognized to confer excess risk of atherosclerotic cardiovascular disease (ASCVD), particularly in younger patients and during periods of active disease. We here synthesize evidence across epidemiology, mechanisms, risk stratification, and management at the IBD-ASCVD interface. Across population cohorts and meta-analyses, IBD associates with modest but consistent increases in ischemic heart disease, cerebrovascular events, and peripheral arterial disease, with higher relative risks for mesenteric ischaemia and for premature events; risk escalates with inflammatory burden and flares, while traditional factors alone partially explain the association. Prolonged corticosteroid exposure correlates with adverse vascular outcomes, whereas effective control of intestinal inflammation, particularly with anti-TNF biologics, appears protective; the absolute cardiovascular risk with Janus kinase inhibitors seems largely determined by baseline risk profile and is low in appropriately selected patients. Proposed drivers include dysbiosis and microbially derived metabolites (e.g., trimethylamine-N-oxide, imidazole propionate), intestinal barrier failure with low-grade endotoxemia and Toll-like receptor-4 activation, neutrophil- and platelet-mediated thromboinflammation, and inflammasome pathways that accelerate atherothrombosis. For risk stratification, non-invasive vascular measures (arterial stiffness, carotid intima-media thickness, coronary artery calcium) and general calculators (SCORE2/ASCVD) are informative, though underestimation in younger patients is possible; expert guidance emphasizes mitigation of inflammatory activity, smoking cessation, prudent steroid use, and lipid monitoring with small-molecule therapy. In conclusion, IBD confers clinically relevant ASCVD risk through immune-microbiome-barrier interactions superimposed on traditional factors. Routine cardiovascular assessment, aggressive control of intestinal inflammation, lifestyle optimization, and judicious therapy selection should be embedded in IBD care, while prospective studies refine prediction tools and test targeted preventive strategies across phenotypes and ages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesAtherosclerosisHumansRisk AssessmentRisk Factors

Stichwörter der Autor:innen

AtherosclerosisCardiovascular eventsInflammatory bowel disease

Autor:innen und Institutionen

  • Digestive Disease Center "CeMAD", Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, 00168, Italy; Dipartimento di Medicina e Chirurgia Traslazionale, Università Catto…
  • Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, 00168, Italy.
  • Digestive Disease Center "CeMAD", Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, 00168, Italy.

Zitieren

APA

Puca, P., Coppola, G., Parello, S., Capobianco, I., Colantuono, S., Scaldaferri, F., & Papa, A. (2025). Atherosclerotic cardiovascular disease and inflammatory bowel disease: epidemiology, pathogenesis and risk assessment. Best Practice & Research Clinical Gastroenterology, 78, 102056. https://doi.org/10.1016/j.bpg.2025.102056

Vancouver

Puca P, Coppola G, Parello S, Capobianco I, Colantuono S, Scaldaferri F, et al. Atherosclerotic cardiovascular disease and inflammatory bowel disease: epidemiology, pathogenesis and risk assessment. Best Practice & Research Clinical Gastroenterology. 2025;78:102056. doi:10.1016/j.bpg.2025.102056

BibTeX
@article{Puca2025,
  author = {Puca, Pierluigi and Coppola, Gaetano and Parello, Simone and Capobianco, Ivan and Colantuono, Stefania and Scaldaferri, Franco and Papa, Alfredo},
  title = {Atherosclerotic cardiovascular disease and inflammatory bowel disease: epidemiology, pathogenesis and risk assessment},
  journal = {Best Practice & Research Clinical Gastroenterology},
  year = {2025},
  volume = {78},
  pages = {102056},
  doi = {10.1016/j.bpg.2025.102056}
}
Kostenlos starten →